^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
WSD0628
i
Other names: WSD0628
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Wayshine Biopharm
Drug class:
ATM kinase inhibitor, Radiosensitiser
Related drugs:
11ms
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
1year
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic | Trial completion date: Oct 2028 --> Feb 2029 | Trial primary completion date: Oct 2027 --> Feb 2028
Trial completion date • Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
1year
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic | Trial primary completion date: Oct 2028 --> Oct 2027
Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
over1year
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic
New P1 trial • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
Share via
